AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNTM
  4. [6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)

[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39152

Quantum BioPharma Ltd.
(Translation of registrant's name into English)

55 University Ave., Suite 1003
Toronto, Ontario M5J2H7, Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Quantum BioPharma Ltd.    
  (Registrant)
   
  
Date: August 4, 2025     /s/ Donal Carroll    
  Donal Carroll
  Chief Financial Officer
  

EXHIBIT INDEX

 

Exhibit Number Description
  
99.1 Press Release dated August 4, 2025

Source:

Stock QNTM logo
Quantum BioPharma Ltd

NASDAQ:QNTM

QNTM Rankings

#7145 Ranked by Market Cap
N/A Ranked by Dividends
#47 Top Loser

QNTM Latest News

Aug 11, 2025
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
Aug 8, 2025
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Aug 7, 2025
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt
Aug 5, 2025
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
Aug 4, 2025
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

QNTM Latest SEC Filings

Aug 11, 2025
[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)
Aug 8, 2025
[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)
Aug 7, 2025
[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)
Aug 5, 2025
[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)
Jul 31, 2025
[6-K] Quantum Biopharma Ltd. Class B Subordinate Voting Shares Current Report (Foreign Issuer)

QNTM Stock Data

89.49M
2.54M
8.79%
23.8%
3.99%
Biotechnology
Healthcare
Canada
Toronto